Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.
The APTIMA Human Papillomavirus (HPV) Assay detects E6/E7 mRNA from 14 human papillomavirus genotypes. Horizon was a population-based split-sample study among well-screened women, with an aim to compare APTIMA, Hybrid Capture 2 (HC2), and liquid-based cytology (LBC) using SurePath samples. APTIMA testing on the PANTHER platform, and HC2 testing on the Rapid Capture System were performed in accordance with protocols agreed on with the manufacturers before the study, on 5070 consecutive, routine, cervical cytology samples from Copenhagen, Denmark. In this high-risk population, 17% of all samples tested positive on APTIMA, 20% of samples tested positive on HC2, and 7% of samples had abnormal cytology. Among the 4411 samples without recent abnormalities, 15% tested positive on APTIMA, 19% tested positive on HC2, and 5% had abnormal cytology. The κ coefficient of 0.75 suggested substantial agreement between APTIMA and HC2. This is the first APTIMA study using SurePath samples on the PANTHER platform. The trends in positivity rates on SurePath samples for APTIMA, HC2, and LBC were consistent with studies based on PreservCyt samples, and the agreement between the two HPV assays was substantial. The high proportions of women testing positive suggest that in countries with a high HPV prevalence, caution will be needed if HPV tests, including mRNA-based tests, are to replace LBC.